-29 EMP(2022.09)
🩸 LIKELY CASUALTIES (AI ESTIMATE):
- 🔴Clinical Development Support (90%) ─ Reason: Trial scope changes; pipeline reprioritization.
- 🔴Early-Stage Discovery Scientists (85%) ─ Reason: Underperforming programs; focus shift.
- 🟡General Administrative Operations (75%) ─ Reason: Overhead reduction for 'efficiency' push.
🤷 CORPORATE BS LEVEL:N/A













